Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Q2 2026 Earnings Presentation
19 slides from Inovio Pharmaceuticals's earnings presentation, August 2026
Slide 1: Second Quarter 2026 Financial Results
Second Quarter 2026 Financial Results August 2026
Slide 2: Agenda
Agenda Introduction Jennie Willson, Director, Communications CEO Perspective & Corporate Progress Jacqueline Shea, PhD, President & Chief Executive Officer INO-3107 Update Michael Sumner, MBBS, MBA, Chief Medical Officer & Head of Development Steve Egge, MBA, Chief Commercial Officer Pipeline Update
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 4: 2Q26 Corporate Update
2Q26 BLA for INO-3107 Advancing Corporate • Late-cycle review meeting completed • Informal clinical meeting held Update • All scheduled inspections conducted • PDUFA target date of October 30, 2026 Commercialization Preparations • Advancing essential launch preparations with the goal of establishing
Slide 5: BLA Review for INO-3107
BLA Review for INO-3107 INO-3107 Targets the Cause of RRP On Track for Oct. 30 Target PDUFA PRIOR TO INO-3107 • Completed late-cycle review meeting and all scheduled FDA inspections • Clinical informal meeting conducted in July following change in CBER & OTP leadership - Presented totality of data s
Slide 6: Accelerated Approval: We Believe INO-3107 Meets FDA Criteria
Accelerated Approval: We Believe INO-3107 Meets FDA Criteria1 Meaningful therapeutic benefit Potential to meet remaining over existing treatments2 critical unmet need EFFICACY SAFETY DIFFERENTIATED MOA • 50% - 100% reduction in surgeries: • No required minimal residual disease • Potential ability to
Slide 7: The need for therapeutic alternatives to surgery in RRP remains immense
“ The need for therapeutic alternatives to surgery in our RRP community remains immense. Every surgery matters, every patient matters, and every patient deserves a treatment that works for them.” Kim McClellan President, RRP Foundation 7
Slide 8: INO-3107 Designed to Deliver What Patients & HCPs Want Most
INO-3107 Designed to Deliver What Patients & HCPs Want Most EFFICACY TOLERABILTY SIMPLICITY Improving response over time Well tolerated Patient-centric treatment • Overall Response Rate (50% to • 41% (13/32) reported treatment- • Designed with no requirement for 100% reduction in surgeries): 72% rel
Slide 9: INO-3107 Offers Competitive Advantages to Current Treatment Options
INO-3107 Offers Competitive Advantages to Current Treatment Options STANDARD OF CARE: INO-3107 PAPZIMEOS SURGERY Reduces number of surgeries post treatment No scoping/surgery required during treatment window to maintain minimal residual disease No potential impact on clinical benefit from pre-existi
Slide 10: Opportunity to Establish INO-3107 as the New Standard of Care in RRP
Opportunity to Establish INO-3107 as the New Standard of Care in RRP* Leverage experienced field teams, targeted marketing and patient support services to: • Drive HCP and patient preference for INO-3107 based on unique and differentiated product profile • Establish broad access among Payers and Hos
Slide 11: INOVIO Development Pipeline
INOVIO Development Pipeline Recent progress on late-stage candidates
Slide 12: Advancing a Diversified Clinical Pipeline
Advancing a Diversified Clinical Pipeline PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION DMAbs INO-5401 VGX-3100 INO-3107 * Various Targets BRCA 1/2 Mutation Anal Dysplasia RRP DPROTs INO-4201 INO-3112 Various targets Ebola Booster Head & Neck Cancer DLNPs INO-6172 INO-5412 Various targets HIV + c
Slide 13: Positive Topline Results from ApolloBio's Phase 3 Trial of VGX-3100
Positive Topline Results from ApolloBio’s Phase 3 Trial of VGX-3100 in Cervical Dysplasia Patients • VGX-3100: INOVIO’s investigational DNA immunotherapy licensed to ApolloBio - ApolloBio plans to use results to support future regulatory submission of VGX-3100 in China • Trial successfully met prede
Slide 14: DNA-Encoded Proteins (DPROT)
DNA-Encoded Proteins (DPROT) Potential as a New Treatment Paradigm in Rare Diseases • Builds on DMAb technology - Targets long-term protein expression, with ability to re-dose due to lack FACTOR VIII PROTEIN of anti-vector immunity STRUCTURE • Aims to address shortcomings of conventional therapeutic
Slide 15: First Quarter 2026 Financial Update
First Quarter 2026 Financial Update
Slide 16: Making Progress on Strategic Goals While Reducing Costs
Making Progress on Strategic Goals While Reducing Costs THREE MONTHS SIX MONTHS ENDED JUNE 30, 2026 (UNAUDITED) ENDED JUNE 30, 2026 (UNAUDITED) % % 2026 2025 CHANGE 2026 2025 CHANGE Operating expenses $18.6 $23.1 (19%) $40.6 $48.2 (16%) Net loss ($6.0) ($23.5) (74%) ($25.7) ($43.2) (41%) Net loss pe
Slide 17: Q&A
Q&A
Slide 18: Progressing Strategy to Unlock the Promise of DNA Medicine
Progressing Strategy to Unlock the Promise of DNA Medicine NEAR TERM MID TERM NEXT GEN Working to Advancing Innovating Deliver INO-3107 Diversified NextGen to Patients Clinical Pipeline DNA Medicines 18
Slide 19: Thank you
Thank you INVESTORS: Peter Vozzo Peter.Vozzo@icrhealthcare.com MEDIA: Jennie Willson Jennie.Willson@inovio.com
Inovio Pharmaceuticals — Q2 2026 Earnings Presentation on 6ix